Fort Point Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Fort Point Capital Partners’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,700	Closed	-$25.2K	–	325
2024 Q1	$25.2K	Hold	1,700	–	–	﹤0.01%	322
2023 Q4	$24.6K	Hold	1,700	–	–	﹤0.01%	300
2023 Q3	$18.4K	Hold	1,700	–	–	﹤0.01%	283
2023 Q2	$21.9K	Hold	1,700	–	–	﹤0.01%	289
2023 Q1	$22.4K	Hold	1,700	–	–	﹤0.01%	268
2022 Q4	$25.5K	Hold	1,700	–	–	﹤0.01%	271
2022 Q3	$20K	Hold	1,700	–	–	﹤0.01%	265
2022 Q2	$19K	Hold	1,700	–	–	﹤0.01%	275
2022 Q1	$51K	Hold	1,700	–	–	0.01%	286
2021 Q4	$45K	Hold	1,700	–	–	0.01%	285
2021 Q3	$62K	Hold	1,700	–	–	0.01%	250
2021 Q2	$74K	Hold	1,700	–	–	0.01%	163
2021 Q1	$58K	Hold	1,700	–	–	0.01%	151
2020 Q4	$60K	Hold	1,700	–	–	0.01%	146
2020 Q3	$41K	Hold	1,700	–	–	0.01%	137
2020 Q2	$31K	Hold	1,700	–	–	0.01%	131
2020 Q1	$27K	Hold	1,700	–	–	0.01%	108
2019 Q4	$36K	Hold	1,700	–	–	0.01%	121
2019 Q3	$32K	Hold	1,700	–	–	0.01%	119
2019 Q2	$44K	Hold	1,700	–	–	0.02%	106
2019 Q1	$44K	Hold	1,700	–	–	0.02%	108
2018 Q4	$39K	Hold	1,700	–	–	0.02%	143
2018 Q3	$55K	Hold	1,700	–	–	0.02%	154
2018 Q2	$48K	Hold	1,700	–	–	0.02%	124
2018 Q1	$60K	Hold	1,700	–	–	0.02%	155
2017 Q4	$66K	Hold	1,700	–	–	0.03%	127
2017 Q3	$43K	Hold	1,700	–	–	0.02%	132
2017 Q2	$46K	Buy	+1,700	New	+$46.5K	0.03%	96

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Fort Point Capital Partners's RIGL Position: Q2 2024 in Review

Fort Point Capital Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 1,700 shares — an estimated $25.2K sold.

Fort Point Capital Partners first reported a position in RIGL in Q2 2017 and held it in 28 quarters. The position peaked at $74K in Q2 2021. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

Fort Point Capital Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Fort Point Capital Partners sold 1,700 Rigel Pharmaceuticals shares in Q2 2024, an estimated $25.2K.
Fort Point Capital Partners first reported a position in Rigel Pharmaceuticals in Q2 2017 and held it in 28 quarters.
Fort Point Capital Partners's Rigel Pharmaceuticals position peaked at $74K in Q2 2021.
91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Fort Point Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.